Insulin adjustments to maintain glycemic control in individuals with type 1 diabetes often lead to wide glucose fluctuations, hypoglycemia, and increased body weight. Dapagliflozin, an insulin-independent sodium-glucose cotransporter 2 (SGLT2) inhibitor, increases glucosuria and reduces hyperglycemia in individuals with type 2 diabetes. The primary objective of this study was to assess short-term safety of dapagliflozin in combination with insulin; secondary objectives included pharmacokinetic, pharmacodynamic, and efficacy parameters.
Insulin therapy for type 1 diabetes presents many challenges to patients and physicians. On a day-to-day basis, marked daily glucose fluctuations and frequent hypoglycemia limit insulin dosing (1) . In the long-term, increasing the insulin dose to achieve and/or maintain glycemic control is associated with weight gain (2) , which may contribute to potential cardiovascular complications (3) .
Dapagliflozin, a highly selective, orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by inhibiting renal glucose reabsorption independently of insulin. In patients with insulin-treated type 2 diabetes, dapagliflozin therapy has been shown to improve glycemic control with attenuation of insulin-associated weight gain and without increasing rates of major hypoglycemia, and also with consistent reductions of systolic blood pressure (4, 5) . This efficacy profile suggests that dapagliflozin may offer a potential therapeutic advance as an adjunct to insulin therapy in patients with type 1 diabetes.
Since the introduction of insulin in 1922, only one new injectable therapeutic class (amylin analog) has been approved for the treatment of type 1 diabetes, but with a black box warning for hypoglycemia. In addition, there are no approved oral therapies for type 1 diabetes, therefore, an unmet need exists for novel therapies in type 1 diabetes. The kidney might become a therapeutic target with the advent of insulin-independent selective orally active glucosuric agents, which could potentially influence the maladaptive reabsorption of glucose, which may perpetuate hyperglycemia, that has been observed in these patients (6).
This pilot study sought to answer the following research questions. First, is the short-term safety and tolerability of dapagliflozin acceptable in patients with type 1 diabetes? Second, are the pharmacokinetic profile and pharmacodynamic activity of dapagliflozin in patients with type 1 diabetes comparable to those previously described in other populations? Third, do the effects of dapagliflozin on efficacy parameters after 7 days of treatment in patients with type 1 diabetes suggest that it may have the potential to be efficacious in these patients?
RESEARCH DESIGN AND METHODS

Study Design
This was a 2-week randomized, doubleblind, parallel-group, placebo-controlled, exploratory phase 2a pilot study, evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of dapagliflozin in patients with type 1 diabetes inadequately controlled with insulin; it was conducted from 3 February 2012 to 17 October 2012. The study complied with the Declaration of Helsinki and the International Conference on Harmonisation/Good Clinical Practice Guidelines, and was approved by institutional review boards and independent ethics committees for the participating centers (clinical trial reg. no. NCT01498185). All participants provided informed consent.
Enrollment Criteria
Inclusion criteria included the following: age range 18-65 years; type 1 diabetes treated with insulin monotherapy, either by multiple daily injections consisting of long-acting (basal) plus short-acting prandial (bolus) insulin or continuous subcutaneous insulin infusion pump, for $12 months; and HbA 1c $7.0% and #10.0% at screening. Exclusion criteria included the following: a history of type 2 diabetes; treatment with oral antihyperglycemic agents within 12 months of study commencement or diabetic ketoacidosis; hospitalization for poor glycemic control; and frequent episodes of hypoglycemia within the previous 24 weeks (see Supplementary Data for detailed lists of the inclusion and exclusion criteria).
Study Procedures and Interventions
Three days prior to randomization, participants were admitted to an inpatient facility for collection of baseline data and confirmation of eligibility. They were subsequently randomly assigned by a computerized interactive voice response system to receive daily doses of dapagliflozin (1, 2.5, 5, or 10 mg) or matching doses of placebo in a 1:1:1:1:1 ratio in addition to their insulin regimen. Randomization was stratified by BMI category (#23 or .23 kg/m 2 ) and insulin administration method (i.e., multiple daily injection or continuous subcutaneous insulin infusion). The investigator, sponsor, and patients remained blinded to treatment allocation throughout the double-blind treatment and the followup periods.
Inpatient double-blind treatment continued for a period of 7 days, during which data were collected and analyzed. During inpatient treatment, standardized diets and guidance on insulin dose adjustment were given. Insulin dose was not proactively reduced at study drug initiation. However, patients and investigators were advised to adjust insulin dosing as needed to avoid hypoglycemia and ensure patient safety. Outpatient double-blind treatment continued for a further 7 days, and, on cessation of doubleblind treatment, follow-up data were collected over another 7 days.
Primary Objective
Short-term Safety and Tolerability
In order to establish the short-term safety and tolerability of dapagliflozin in combination with insulin, data on safety and tolerability were analyzed after a total of 14 days of exposure. Key parameters included general adverse events (AEs), treatment discontinuations, hypoglycemic events, and genital and urinary tract infections, as well other parameters of interest, such as total daily fluid intake, total daily urine output, body weight, blood pressure, and daily urine ketones.
Secondary Objectives
Pharmacokinetic and Pharmacodynamic Parameters
In order to establish whether the pharmacokinetic profile and pharmacodynamic effect on urinary glucose excretion was similar to that already well described in other populations, the following analyses were conducted. Pharmacokinetic parameters for dapagliflozin and its major inactive metabolite dapagliflozin 3-Oglucuronide (D3OG) analyzed were as follows: maximum observed plasma concentration (C max ); time of maximum observed plasma concentration (T max ); area under the concentration-time curve in one dosing interval (AUCt); and ratio of metabolite to parent AUC (corrected for molecular weight). The pharmacodynamic parameter analyzed was the mean change from baseline in 24-h urine glucose at day 7.
Exploratory Efficacy Parameters
To explore the potential of dapagliflozin as an adjunctive treatment for type 1 diabetes and to guide future clinical study design considerations, the efficacy parameters analyzed were the mean changes from baseline at day 7 in the following: mean glucose based upon 7-point central laboratory glucose measurements obtained before and after each meal and at bedtime; fasting plasma glucose (FPG) ; daily average glucose (DAG); SD of DAG; and mean amplitude of glucose excursion (MAGE). The latter three parameters were derived from 24-h continuous glucose monitoring (CGM) using a Dexcom SEVEN PLUS device. The CGM system, which remained blinded to the patient and site staff during the recording, recorded data approximately every 5 min and downloaded the data wirelessly into a data file. Site staff and patients were fully trained to operate and calibrate the CGM device according to the manufacturer's instructions. Also analyzed were the mean percent changes from baseline at day 7 in daily basal, bolus, and total insulin doses.
Statistical Analysis
In this exploratory pilot study, mean changes from baseline and two-sided 95% CIs were calculated. No statistical hypothesis testing was performed, and no P values were calculated. For the analysis of pharmacokinetic parameters, geometric means and coefficients of variation were summarized for C max , AUCt, and the ratio of metabolite to parent AUC. Medians and ranges were summarized for T max . For the pharmacodynamic analysis of 24-h urine glucose, no dapagliflozin versus placebo mean difference calculations were planned. For the efficacy parameter, 7-point mean glucose, dapagliflozin versus placebo mean differences, and 95% CIs were prespecified. For the remaining efficacy parameters, no dapagliflozin versus placebo mean difference calculations were planned. For the analysis of the percent changes in insulin dose, values were log transformed prior to analysis; resulting geometric mean estimates and 95% CIs on the log scale were then back-transformed using the formula 100 3 (e Estimate 2 1) to obtain the mean percent changes from baseline and their associated 95% CIs.
RESULTS
Patients
Overall, the baseline mean 6 SD HbA 1c was 8.46 6 0.81% and the mean age was 35.3 6 12.9 years. Baseline urinary glucose, FPG, and HbA 1c trended higher and were more variable in the placebo group compared with the dapagliflozin groups ( Table 1) . Of the 70 patients randomized, 62 (88.6%) completed the study ( Supplementary Fig. 1 ). Data are reported as the mean (SD), unless otherwise stated. N is the number of randomized patients who took at least one dose of double-blind study medication. BP, blood pressure; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease. *Baseline data missing in one patient.
Short-term Safety and Tolerability
AEs are summarized in Table 2 . One serious AE (gastroparesis) not related to treatment was reported in the dapagliflozin 5 mg group in a patient with a history of gastroparesis, which led to discontinuation of treatment. A high percentage of patients in all treatment groups experienced at least one episode of hypoglycemia with no apparent relationship to dapagliflozin dose (Table  2) ; one event on day 6 in the dapagliflozin 10 mg group was major (defined as requiring third-party assistance and a plasma glucose value ,3.0 mmol/L), which was related to the noncompliance of the patient to reduce insulin dosing as instructed by the investigator. This event led to discontinuation of treatment on day 8 because of the investigator's concerns regarding the patient's compliance with insulin dosing instructions and nutrition during the outpatient period. One genitourinary infection occurred in each of the placebo and dapagliflozin 1, 2.5, and 5 mg groups (Table 2 ). There were no apparent effects of dapagliflozin on fluid intake, body weight, or blood pressure in this relatively normal weight and normotensive population (Supplementary Table 1 ). Total daily urine output tended to show numeric increases in all groups, but this increase was larger in the placebo group compared with the dapagliflozin groups (Supplementary Table 1). Positive results of urine ketone tests were observed in all groups at baseline and appeared to decrease in the placebo and dapagliflozin 1 and 2.5 mg groups during study drug administration. No instance of diabetic ketoacidosis occurred.
Pharmacokinetic and Pharmacodynamic Parameters
Steady-state pharmacokinetic results showed that both C max and AUCt appeared to be dose proportional across all dose groups for both dapagliflozin and its metabolite D3OG. Dapagliflozin Table 2 Data are reported as n (%), unless otherwise stated. N is the number of patients exposed to study medications. SAE, serious AE; UTI, urinary tract infection. *Counted up to 4 days after last dose date. †Data represent a single patient with gastroparesis on day 10, who discontinued the study. ‡Counted up to 30 days after last dose date. §Hypoglycemic events were collected separately from general AEs. If hypoglycemic events qualified as SAEs, these events were to be collected and summarized with all other SAEs. Otherwise, hypoglycemic events were collected and summarized separately up to 4 days after the date of the last dose. Major hypoglycemia was defined as a symptomatic episode requiring external (third-party) assistance due to severe impairment in consciousness or behavior with capillary or plasma glucose values of ,3.0 mmol/L (,54 mg/dL) and prompt recovery after glucose or glucagon administration. Minor hypoglycemia was defined as either a symptomatic episode with a capillary or plasma glucose value of ,3.5 mmol/L (,63 mg/dL), regardless of the need for external assistance; or an asymptomatic capillary or plasma glucose value of ,3.5 mmol/L (,63 mg/dL) that did not qualify as a major episode. Other hypoglycemia was defined as a suggestive episode reported but not meeting the criteria for major or minor episodes. ||One patient was listed as having discontinued study participation due to hypoglycemia. The patient experienced a major hypoglycemia episode on day 6 while receiving dapagliflozin 10 mg plus insulin, which the investigator felt to be related to a failure of the patient to reduce insulin as instructed. The patient was allowed to continue in the inpatient portion of the study, but the investigator expressed concerns regarding the compliance of this patient as an outpatient, and so the patient had study participation discontinued on day 8. ¶A prespecified list of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA version 15.1) was used to identify events of genital infection and of UTI in the database.
was rapidly absorbed after oral administration, with median T max ranging from 0.50 to 1.00 h. Similarly, the median T max values for D3OG ranged from 1.00 to 2.00 h. The ratio of metabolite to parent AUC was consistent across all dose groups, ranging from 0.66 to 0.76 (Supplementary Table 2 ).
Consistent with its mechanism of action, a dose-dependent increase in 24-h urine glucose was observed with dapagliflozin ( Fig. 1A) , but this was not statistically tested. In contrast, the 24-h urine glucose decreased in the placebo group.
Exploratory Efficacy Parameters
Glycemic efficacy parameters at day 7 are summarized in Fig. 1B-F . For mean glucose measurements derived from 7-point glucose monitoring (Fig. 1B and  Supplementary Table 3 ), no differences between the placebo and dapagliflozin groups were observed. For all other glycemic efficacy parameters (Fig. 1C-F) , the 95% CIs of the mean for all dapagliflozin doses overlapped those of placebo. Among the dapagliflozin groups, the following dose-related trends were suggested: FPG, DAG, SD of DAG, and MAGE showed greater numeric reductions at day 7 with the dapagliflozin 5 and 10 mg doses versus the lower dapagliflozin doses (Fig. 1C-F) . In addition, the dapagliflozin 5 and 10 mg doses were associated with reductions in the mean percent change from baseline at day 7 in total insulin dose of 219.3% (95% CI 230.1 to 26.8) and 216.2% (95% CI 229.4 to 20.5), respectively; however, it should again be noted that the 95% CIs for all dapagliflozin doses overlapped those for placebo (Fig. 2) .
CONCLUSIONS
No unexpected short-term safety concerns were identified with dapagliflozin therapy in patients with type 1 diabetes. A high percentage of patients experienced at least one hypoglycemic event across all treatment groups, with the number of events varying substantially between groups. Despite this variation, hypoglycemia rates appeared to show no relationship to dapagliflozin dose, and it was reassuring that there was no evidence of a dramatic increase in major hypoglycemic events in patients who received dapagliflozin in combination with insulin; of 57 dapagliflozintreated patients, only one patient experienced a major hypoglycemia event. It should be noted that insulin doses were not proactively reduced in this study; however, on initiation of dapagliflozin therapy, caution and/or proactive insulin dose reduction may be required, given that the insulin dose was reduced in the dapagliflozin 5 and 10 mg groups. In addition, further larger studies of longer duration are required to fully assess hypoglycemia rates with Figure 2 -Mean percent change from baseline at day 7 for basal daily insulin dose (A), bolus daily insulin dose (B), and total daily insulin dose (C). ○, placebo plus insulin; ◆, dapagliflozin 1 mg plus insulin; ▲, dapagliflozin 2.5 mg plus insulin; ▼, dapagliflozin 5 mg plus insulin; and -, dapagliflozin 10 mg plus insulin. Values below the data points represent the mean (95% CI), number of observations, and baseline mean (SD). BL, baseline; D, change; IU, international units. n is the number of randomized and treated subjects with nonmissing baseline and day 7 values. Insulin mean percent change from baseline was calculated using the geometric mean and was back-transformed from results calculated under logarithmic transformation.
